# EDGAR Filing Document

**Accession Number:** 0001808865
**File Stem:** 0000950170-25-087429
**Filing Date:** 2025-6
**Character Count:** 6271
**Document Hash:** 3323b02eb68b796c42b454149f183d20
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-25-087429.hdr.sgml**: 20250617

**ACCESSION NUMBER**: 0000950170-25-087429

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20250617

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250617

**DATE AS OF CHANGE**: 20250617

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** iTeos Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001808865
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39401
- **FILM NUMBER:** 251053860

**BUSINESS ADDRESS:**
- **STREET 1:** 321 ARSENAL STREET
- **STREET 2:** BLDG 312, FLOOR 3, SUITE 301
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472
- **BUSINESS PHONE:** 857-204-4583

**MAIL ADDRESS:**
- **STREET 1:** 321 ARSENAL STREET
- **STREET 2:** BLDG 312, FLOOR 3, SUITE 301
- **CITY:** WATERTOWN
- **STATE:** MA
- **ZIP:** 02472

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## **FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** June 17, 2025<br>

------

iTeos Therapeutics, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-39401 | 84-3365066 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 321 Arsenal Street  |  |  |
| Watertown **,** Massachusetts |  | 02472 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 339 217 0161<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, $0.001 par value per share | ITOS | The Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

------

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## **Item 5.07 Submission of Matters to a Vote of Security Holders.** 
iTeos Therapeutics, Inc. (the "<u>Company</u>") held its Annual Meeting of Stockholders (the "<u>Annual Meeting</u>") on June 17, 2025. As of April 21, 2025, the record date for the Annual Meeting, there were 38,273,795 shares of the Company's common stock outstanding and entitled to vote at the Annual Meeting. There were 33,554,964 shares of common stock entitled to vote at the Annual Meeting present online or represented by proxy, which represented 87.67% of the outstanding shares entitled to vote at the Annual Meeting, which constituted a quorum for the transaction of business. The Company's stockholders voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 24, 2025: (i) to elect Tony Ho, Robert Iannone and Ann D. Rhoades as Class II directors, each to serve for a three-year term expiring at the Company's 2028 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal and (ii) to ratify the appointment of Deloitte Bedrijfsrevisoren / Réviseurs d'Entreprises BV/SRL as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The final voting results for the Annual Meeting are as follows:

The Company's stockholders elected each of the Class II director nominees. The votes cast at the Annual Meeting were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Class II Director Nominee** | **For** | **Withheld** | **Broker Non-Votes** |
| Tony Ho | 21,907,643 | 6,775,693 | 4,871,628 |
| Robert Iannone<br>Ann D. Rhoads | 24,909,798<br>20,985,311  | 3,773,538<br>7,698,026 | 4,871,628<br>4,871,627 |

---

The Company's stockholders approved the ratification of Deloitte Bedrijfsrevisoren / Réviseurs d'Entreprises BV/SRL as the Company's independent registered public account firm. The votes cast at the Annual Meeting were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **For**  | **Against**  | **Abstain**  | **Broker Non-Vote**  |
| 33,347,344 | 24,081 | 183,538 | 1 |

---

No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | iTeos Therapeutics, Inc. |
| Date: | June 17, 2025 | By:  | /s/ Michel Detheux |
|  |  |  | Michel Detheux, Ph.D.<br>President and Chief Executive Officer |

---

------